Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Specialized Laboratory Consumables & Reagents

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract for Specialized Laboratory Consumables and Reagents supports prime contractors working on NIH NIDDK/NHLBI CaRe-T1D Consortium projects. The scope of work involves the delivery of physical laboratory supplies, sequencing kits, high-purity reagents for omics sequencing, and specialized antibodies specifically used for studying endothelial dysfunction and cardiac autonomic neuropathy. Managed under the Department of Health and Human Services for the National Institutes of Health, the contract falls under NAICS code 325182. A critical requirement for the provider is the maintenance of ISO 9001 quality management certification to ensure the standards of the supplied materials.

General Info

Subcontract for NIH laboratory consumables, reagents, and antibodies requiring ISO 9001 certification.

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

325182 - Carbon Black ManufacturingView NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of RFA-DK-27-108.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedSep 18

subcontract

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Supplies high-purity reagents and specialized antibodies for prime contractors on NIH NIDDK/NHLBI CaRe-T1D Consortium projects. Provides antibodies for cardiac autonomic neuropathy, endothelial dysfunction, and high-fidelity reagents for omics sequencing. Requires ISO 9001 quality management certification. Delivers physical laboratory supplies and sequencing kits.

Similar Contracts

Same NAICS industry code

Laboratory Reagents and Consumables Supplier

248-NETWORK Contract Office 8 (36C248)

POSTED

DEADLINE

Synthetic Nucleic Acid Supply & SynthesisThis subcontract opportunity with the Advanced Research Projects Agency for Health (ARPA-H) under the Department of Health and Human Services involves the procurement of synthetic nucleic acids or the provision of benchtop synthesis equipment for prime contractors. The selected provider will be responsible for delivering synthetic DNA/RNA or installing synthesis hardware, ensuring all operations strictly adhere to the Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. The contract is categorized under NAICS code 325182 and is centered in Washington. Interested parties must submit their responses by the deadline of December 8, 2026, following the posting date of July 13, 2026.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

about 2 months ago

DEADLINE

Bioprocess Scale-Up & Bioreactor EngineeringThis subcontract, titled Bioprocess Scale-Up and Bioreactor Engineering, focuses on transitioning engineered enzymes from laboratory scale to industrial production for partners collaborating with Los Alamos National Laboratory. The primary objective is to deliver a scalable production process for thermostable PETase enzymes through the design and operation of bioreactor systems, fermentation process optimization, and the use of scale-up modeling software. Managed by Triad as a Department of Energy contractor, the work will be performed in Los Alamos, New Mexico. The opportunity is categorized under NAICS code 325182, with a response deadline set for October 1, 2026.

Triad - DOE Contractor

POSTED

DEADLINE

Specialized Consumables & Reagent SupplyThis subcontract focuses on the supply of specialized consumables and reagents to support prime contractors working on National Cancer Institute research projects under the National Institutes of Health. The scope of work involves the manufacture and delivery of high-purity reagents, custom-synthesized compounds, and specialized antibodies essential for various experimental phases. To ensure quality and compliance, the provider must supply a Certificate of Analysis and purity certifications for all chemical and biological materials delivered. The opportunity is categorized under NAICS code 325182 and is managed by the Department of Health and Human Services. Interested parties must submit their responses by November 10, 2026, following the posting date of June 3, 2026. This contract is designed to ensure that critical biological and chemical agents are available to maintain the integrity and progress of cancer research initiatives.

National Institutes Of Health

POSTED

DEADLINE

Fermentation Media and Lab Consumables Supplier

National Science Foundation

POSTED

DEADLINE

Specialized Biochemical/Medical Material Supplier

National Science Foundation

POSTED

DEADLINE

Specialized Laboratory Supplies and ConsumablesThis subcontract with the National Institutes of Health under the Department of Health and Human Services focuses on the procurement of specialized laboratory supplies and consumables. The contractor is responsible for manufacturing and delivering high-purity chemicals, custom primers, specialized biological reagents, antibodies, and custom-synthesized materials to support prime investigators on NIH/NHLBI research grants. The agreement covers the production and physical delivery of these materials directly to the designated research sites. This opportunity, categorized under NAICS code 325182, was posted on May 12, 2026, with a response deadline set for November 7, 2028.

National Institutes Of Health

POSTED

DEADLINE

in about 2 years

Laboratory Supplies and Specialized ReagentsThis subcontract under the National Institutes of Health within the Department of Health and Human Services focuses on the provision of laboratory supplies and specialized reagents for prime contractors engaged in research projects. The scope of work involves delivering physical laboratory supplies, including high-purity reagents, custom-synthesized compounds, and specialized cell lines. To ensure operational standards, the provider must maintain quality control certifications and strictly adhere to NIH material transfer agreements. The contract is categorized under NAICS code 325182, with a response deadline set for June 15, 2028.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

Limited Competition: John Lewis NIMHD Research Endowment Program (S21 Clinical Trial Not Allowed)The John Lewis NIMHD Research Endowment Program, administered by the National Institutes of Health under the Department of Health and Human Services, is designed to enhance research infrastructure and training capacity at eligible institutions of higher education to support health disparities research. The program focuses on four strategic objectives: upgrading physical infrastructure and equipment, developing technical expertise, expanding relevant academic science programs, and recruiting high-level researchers for faculty positions. It is important to note that this program provides institutional support and does not directly fund specific research projects. This opportunity is a forecast for a limited competition, meaning only eligible organizations will be invited to apply. Applications will undergo a standard NIH peer-review process, and funding will be awarded based on the merit of the proposal. Clinical trials are not allowed under this specific program.

Administration of Public Health Programs

POSTED

DEADLINE

NIH Director's Pioneer Award (DP1 Clinical Trial Optional)The NIH Director's Pioneer Award, managed by the National Institutes of Health under the Department of Health and Human Services, is a forecast opportunity designed to support exceptionally creative scientists. This award is part of the NIH Common Fund's High-Risk, High-Reward Research Program and targets bold, innovative research that has the potential to transform scientific areas relevant to the NIH mission. To qualify, proposed projects must explore new scientific directions that differ significantly from the investigator's previous work and existing research in the field. Applications are accepted across all scientific areas relevant to the NIH, and clinical trials are optional for this award. The program is intended for investigators pursuing high-risk research that could lead to major breakthroughs. Interested parties can contact the NIH Director's Pioneer Award Program for further details via the provided email contact.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

NIH Director's Early Independence Award (DP5 Clinical Trial Optional)The NIH Director's Early Independence Award, administered by the National Institutes of Health under the Department of Health and Human Services, is designed to accelerate the transition of outstanding early-career investigators into independent research roles. This award targets individuals who have recently completed their doctoral degrees or post-graduate clinical training and wish to bypass the traditional postdoctoral path. As part of the NIH Common Fund's High-Risk, High-Reward Research Program, the award is open to applications across all scientific fields that align with the NIH mission. This specific opportunity is listed as a forecast with the title NIH Director's Early Independence Award (DP5 Clinical Trial Optional). Interested parties can contact the NIH Director's Early Independence Award Program via email at earlyindependence@od.nih.gov for further information. Additional details and application processes are available through the official grants.gov portal.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

NIH Director's New Innovator Award (DP2 Clinical Trial Optional)The NIH Director's New Innovator Award, managed by the National Institutes of Health under the Department of Health and Human Services, is a forecast opportunity designed to support early-stage investigators. This award focuses on funding exceptionally creative and bold research projects that have the potential to transform scientific fields relevant to the NIH mission. It is part of the broader High-Risk, High-Reward Research Program within the NIH Common Fund and accepts applications across all relevant scientific disciplines. The award is identified as DP2 and notes that clinical trials are optional. Interested parties can contact the NIH Director's New Innovator Award Program via email for further information. This initiative serves as a complement to other NIH programs aimed at supporting the development of early-career researchers pursuing high-impact innovation.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

NIH Director's Transformative Research Award (R01 Clinical Trial Optional)The NIH Director's Transformative Research Award, managed by the National Institutes of Health under the Department of Health and Human Services, provides funding for individual scientists and research teams engaged in bold and unconventional research. This initiative is part of the NIH Common Fund's High-Risk, High-Reward Research Program and aims to support projects that can establish new scientific paradigms, create transformative technologies, or develop innovative clinical approaches. This specific opportunity is listed as a forecast with a posted date of September 3, 2026, and is categorized as an R01 award where clinical trials are optional. Interested parties can contact the NIH Director's Transformative Research Award Program via email for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)The National Institute on Minority Health and Health Disparities within the National Institutes of Health is issuing a forecast for planning grants titled Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes. These grants are designed to support preparatory, feasibility, and pilot activities that advance intervention development or solutions-oriented etiologic studies. A mandatory requirement for all projects is that they must be co-developed with community partners to ensure the effectiveness of the health outcomes being addressed. Priority areas for funding include formative studies on understudied contributors to chronic diseases like cancer and diabetes, as well as the adaptation and pilot-testing of interventions for maternal and infant health. Additionally, the program seeks feasibility and acceptability testing for strategies aimed at reducing behavioral risk factors, such as poor nutrition and smoking, to promote sustained behavior change and measurable improvements in health for NHPI populations.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources (S15 Clinical Trial Not Allowed)The National Institutes of Health, under the Department of Health and Human Services, has issued a forecast for the Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources program. This funding opportunity is designed for eligible shared biomedical research facilities, such as core facilities, biorepositories, and model resource facilities, to acquire new small instruments or scientific equipment. The primary objective is to enhance the operational efficiency and capabilities of resources shared by multiple researchers. Priority is given to requests for small instruments utilizing emerging technologies or those that generate physical, chemical, or biomaterial outputs rather than standard digital data. It is important to note that funding is restricted and cannot be used for building-level infrastructure or highly specialized instruments that only indirectly support research. Clinical trials are not allowed under this specific opportunity.

Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

DEADLINE

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2The National Institutes of Health, through the National Institute on Drug Abuse, is forecasting Phase 2 of the Single Cell Opioid Responses in the Context of HIV (SCORCH) program. This initiative builds upon Phase 1 research by utilizing single-nucleus datasets from human and animal postmortem brain tissue to investigate the interactions between Substance Use Disorder and HIV disease progression within the Central Nervous System. The program aims to employ advanced single cell approaches, including the study of RNA splicing, epigenomic features, and spatial interactions, to conduct both data mining and hypothesis-driven research. The ultimate goal is to enhance the mechanistic understanding of how these conditions affect the brain at subcellular and circuit levels to identify potential targets for novel therapeutic interventions.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Translational Research in Maternal and Pediatric Pharmacology and TherapeuticsThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to issue a Notice of Funding Opportunity for translational research in maternal and pediatric pharmacology and therapeutics. This initiative aims to improve safe and effective precision therapeutics for pregnant women, lactating women, infants, children, and adolescents. The program focuses on advancing precision medicine via novel tools and technologies, developing safer therapeutics, improving patient-provider communication regarding drug safety, and scaling evidence-based interventions. This forecast is part of the agency's stewardship of the Best Pharmaceuticals for Children Act and recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. While the project outlines clear goals for enhancing medication effectiveness and safety across these specific patient populations, applications are not currently being solicited. Interested parties can coordinate with the Obstetric and Pediatric Pharmacology and Therapeutics Branch for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)The Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) is a legislatively mandated Centers of Excellence program managed by the National Institutes of Health under the Department of Health and Human Services. This initiative focuses on expanding and intensifying basic, translational, and clinical research regarding muscular dystrophy through interdisciplinary collaboration and shared resources. By supporting innovative center-based projects and providing robust training environments for emerging scientists, the program aims to achieve research outcomes that exceed the capabilities of stand-alone grants. A critical component of the program is its commitment to patient-centered research, actively engaging patient and advocacy communities to increase awareness and ensure that study designs are informed by patient perspectives. This forecast opportunity is supported by several grant authorities, including 42 U.S.C. 281, 283g, 285g, and 284h. Interested parties can coordinate with the NICHD Intellectual and Developmental Disabilities Branch for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is seeking a coordinated, milestone-driven research project titled Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes. This initiative aims to integrate large, longitudinal, and multimodal datasets from various T1D research consortia to examine how different biological processes, tissues, and organs interact to drive the development and progression of the disease. By combining human pancreas and clinical data, the project seeks to uncover new insights into T1D biology, identify biomarkers, and inform personalized approaches for prevention and treatment. To achieve these goals, the project will focus on the development and testing of advanced multimodal AI models and AI-enabled research workflows. Key technical objectives include creating new methods for data integration and generating privacy-preserving synthetic datasets. This effort is designed to move beyond the limitations of individual studies to provide a comprehensive understanding of the different forms and stages of Type 1 Diabetes, ultimately accelerating the advancement of precision medicine.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Established Clinician Investigator Award to Support Mentoring (KS1)The Established Clinician Investigator Award to Support Mentoring (KS1) is a forecast opportunity issued by the National Institutes of Health under the Department of Health and Human Services. This award is designed to provide established clinician investigators with a sustained period of protected time, enabling them to deliver high-quality mentoring and guidance to early-career clinician research scientists. The program is managed by the Division of Biomedical Research Workforce, which serves as the primary point of contact for interested parties. While specific performance locations and set-aside details are not listed, the award aims to strengthen the pipeline of clinician researchers through structured mentorship support.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 650+ contractors already using CLEATUS